(Note: This is Biophytis’ IPO of 1.2 million American Depositary Shares (ADS), with each ADS representing 10 ordinary shares. Technically this is an uplift or an “uplisting” of Biophytis stock to the NASDAQ, instead of a traditional IPO. The French biotech’s ordinary shares are listed on the Euronext Growth exchange in Paris under the symbol “ALBPS”.)

We are a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Our goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need. To accomplish this goal, we have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

(Note: Biophytis priced its U.S. IPO on Feb. 9, 2021, of 1.2 million ADS, the same number of ADS in the prospectus,  at $16.75 per ADS to raise $20.1 million. The IPO price was slightly above the mid-point of the $15-to-$18 price range.)